Sinocelltech Group Ltd
SSE:688520
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
31.32
56
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sinocelltech Group Ltd
Net Issuance of Debt
Sinocelltech Group Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Sinocelltech Group Ltd
SSE:688520
|
Net Issuance of Debt
ÂĄ877.1m
|
CAGR 3-Years
47%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Net Issuance of Debt
ÂĄ2.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
||
Akeso Inc
HKEX:9926
|
Net Issuance of Debt
ÂĄ1.1B
|
CAGR 3-Years
219%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Issuance of Debt
ÂĄ38m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Net Issuance of Debt
-ÂĄ2.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
72%
|
CAGR 10-Years
28%
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Issuance of Debt
ÂĄ358.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
Sinocelltech Group Ltd
Glance View
Sinocelltech Group Ltd. engages in the research and development, and manufacture of biopharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 1,353 full-time employees. The company went IPO on 2020-06-22. The firm focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The firm is also engaged in asset leasing business and payment collection business.
See Also
What is Sinocelltech Group Ltd's Net Issuance of Debt?
Net Issuance of Debt
877.1m
CNY
Based on the financial report for Dec 31, 2023, Sinocelltech Group Ltd's Net Issuance of Debt amounts to 877.1m CNY.
What is Sinocelltech Group Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
47%
Over the last year, the Net Issuance of Debt growth was 53%. The average annual Net Issuance of Debt growth rates for Sinocelltech Group Ltd have been 47% over the past three years .